The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors

2004 ◽  
Vol 47 (4) ◽  
pp. 527-537 ◽  
Author(s):  
Lucinda J. Steward ◽  
Matthew D. Kennedy ◽  
Brian J. Morris ◽  
Judith A. Pratt
Keyword(s):  
Prefrontal Cortex ◽  
Atypical Antipsychotic ◽  
Antipsychotic Drug ◽  
Atypical Antipsychotic Drug

ICI 204,636: A new and novel atypical antipsychotic drug

1990 ◽  
Vol 3 (1) ◽  
pp. 46
Author(s):  
J.B. Malick ◽  
B.M. Migler ◽  
A.I. Salama ◽  
J.M. Goldstein ◽  
C.F. Saller ◽  
...  
Keyword(s):  
Atypical Antipsychotic ◽  
Antipsychotic Drug ◽  
Atypical Antipsychotic Drug ◽  
Ici 204,636

Psychopharmacology of olanzapine

1999 ◽  
Vol 174 (S38) ◽  
pp. 52-58 ◽  
Author(s):  
C. M. E. Stephenson ◽  
L. S. Pilowsky
Keyword(s):  
Side Effects ◽  
Atypical Antipsychotic ◽  
Antipsychotic Drug ◽  
Therapeutic Efficacy ◽  
Atypical Antipsychotics ◽  
Extrapyramidal Side Effects ◽  
Atypical Antipsychotic Drug ◽  
Blood Monitoring

The development of atypical antipsychotics has revolutionised the treatment of schizophrenia, as well as providing new insights into its cause. The archetypal atypical antipsychotic is clozapine, which has therapeutic advantages over traditional antipsychotics, as well as a low potential for producing extrapyramidal side-effects (EPS) (Kane et al, 1988). However, clozapine causes agranulocytosis in 1% of patients, and there has consequently been a search for novel atypical antipsychotics, as efficacious as clozapine, but without the need for intensive blood monitoring. There has been much discussion of the definition and characteristics of an atypical antipsychotic drug, and an operational understanding seems to have been agreed upon, that atypical drugs have therapeutic efficacy in treating schizophrenia, without producing EPS (Deutch et al, 1991; Kerwin, 1994).

Sign in / Sign up

Export Citation Format

Share Document